RhumbLine Advisers
SLDB icon

RhumbLine Advisers’s Solid Biosciences SLDB Stock Holding History

RhumbLine Advisers’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
105,068
+22,965
+28% +$174K ﹤0.01% 2288
2026
Q1 		$591K Sell
82,103
-469
-0.6% -$3.01K ﹤0.01% 2505
2025
Q4 		$466K Sell
82,572
-11,709
-12% -$63.5K ﹤0.01% 2704
2025
Q3 		$582K Sell
94,281
-7,888
-8% -$46.1K ﹤0.01% 2589
2025
Q2 		$498K Buy
102,169
+62,747
+159% +$222K ﹤0.01% 2687
2025
Q1 		$146K Sell
39,422
-4,255
-10% -$18.2K ﹤0.01% 3268
2024
Q4 		$175K Buy
43,677
+4,161
+11% +$22.9K ﹤0.01% 3263
2024
Q3 		$275K Buy
39,516
+5,743
+17% +$46.6K ﹤0.01% 3069
2024
Q2 		$191K Buy
+33,773
New +$302K ﹤0.01% 3244
2024
Q1 		– Hold
0
– – – 4247
2023
Q4 		– Hold
0
– – – 4265
2023
Q3 		– Sell
-27
Closed -$105 – 4305
2023
Q2 		$146 Buy
+27
New +$152 ﹤0.01% 4363
2022
Q2 		– Sell
-4,777
Closed -$86K – 3220
2022
Q1 		$86K Sell
4,777
-483
-9% -$8.52K ﹤0.01% 2914
2021
Q4 		$138K Buy
5,260
+286
+6% +$8.74K ﹤0.01% 2901
2021
Q3 		$178K Buy
4,974
+112
+2% +$4.76K ﹤0.01% 2926
2021
Q2 		$267K Buy
4,862
+2,525
+108% +$167K ﹤0.01% 2829
2021
Q1 		$194K Buy
2,337
+4
+0.2% +$443 ﹤0.01% 2839
2020
Q4 		$265K Buy
2,333
+444
+24% +$28.1K ﹤0.01% 2719
2020
Q3 		$58K Sell
1,889
-470
-20% -$18K ﹤0.01% 2939
2020
Q2 		$104K Buy
2,359
+582
+33% +$24.2K ﹤0.01% 2961
2020
Q1 		$64K Buy
1,777
+50
+3% +$2.47K ﹤0.01% 2839
2019
Q4 		$115K Buy
1,727
+138
+9% +$15.2K ﹤0.01% 2862
2019
Q3 		$247K Buy
1,589
+272
+21% +$30.8K ﹤0.01% 2667
2019
Q2 		$114K Buy
1,317
+304
+30% +$33.2K ﹤0.01% 2909
2019
Q1 		$140K Sell
1,013
-30
-3% -$7.52K ﹤0.01% 2813
2018
Q4 		$419K Buy
1,043
+382
+58% +$180K ﹤0.01% 2380
2018
Q3 		$468K Buy
661
+89
+16% +$55.9K ﹤0.01% 2306
2018
Q2 		$306K Buy
+572
New +$176K ﹤0.01% 2522

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's SLDB Position: Q2 2026 in Review

RhumbLine Advisers increased its Solid Biosciences (SLDB) stake by 28% in Q2 2026, buying an estimated $174K and bringing the position to 105,068 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2288.

RhumbLine Advisers first reported a position in SLDB in Q2 2018 and has held it in 26 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • RhumbLine Advisers held 105,068 shares of Solid Biosciences worth $1.05M as of Q2 2026.
  • RhumbLine Advisers bought 22,965 Solid Biosciences shares in Q2 2026, an estimated $174K.
  • Solid Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2288 holding.
  • RhumbLine Advisers first reported a position in Solid Biosciences in Q2 2018 and has held it in 26 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.